Clinical trial · Interventional
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas
NCT04669951CI-TRIAL-00052080completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophagus Cancer, Adenocarcinoma | Esophageal Adenocarcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| uPAR immunohistochemistry | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- uPAR expression
- description
- Immunohistochemistry
- interventionNames
- Other: uPAR immunohistochemistry
Primary outcomes (2)
- measure
- uPAR microexpression
- timeFrame
- Up to 6 months
- description
- Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively. This will be done by a pathology analysis of gastroesophageal cancer resections.
- measure
- Tumor-to-background ratio
- timeFrame
- Up to 6 months
- description
- A pathology staining will determine the uPAR in the tumor compared with the healthy cells.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years old. * Patients who underwent curatively intended surgery for gastroesophageal cancer * Patients who underwent surgery after 01-01-2016. Exclusion Criteria: * Patients who applied for an exception from medical research at the "National Registry of Tissue Use." * Patients with other histological subtypes than adenocarcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.